Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07407894
Recruiting Not applicable

iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

NCT07407894 · tracked via the Priya Life Science USA tracker
Sponsor
Synbiotic Health
Phase
Not applicable
Started
2026-02-01
Last updated
2026-04-22

Condition(s) studied

Healthy AgingAnti Aging

Investigational drug(s) / intervention(s)

Bifidobacterium adolescentis iVS-1Placebo

Bifidobacterium adolescentis iVS-1: B. adolescentis iVS-1 (probiotic capsule) delivered orally once daily at a minimum of 8 billion CFU/day

Placebo: Placebo capsule delivered orally once daily

Study summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 40-75 years. * BMI: 20-34.9 kg/m². * Able and willing to sign informed consent and participate for the study duration. Exclusion Criteria: * Chronic disease history (liver, kidney, heart). * Current pregnancy and/or lactating. * Colonoscopy and/or its preparation within 4 weeks of screening. * Those who intend to have children during study period. * Current probiotic, prebiotics and/or metabolic-altering supplement use. * Those who are unable to cooperate with investigators and testing. * Known history of cancer and/or ongoing cancer treatments. * Abuse of drugs, alcohol, tobacco, nicotine and other substances. * History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related. * History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries. * Type 1 or 2 diabetes mellitus. * Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable. * Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc. * Significant weight loss (\>20%) in prior one month. * Conditions affecting safety or outcome integrity.

Primary outcome measure(s)

  • Change in Biological Aging Biomarkers — Baseline to Day 150
    Changes in gene expression of biomarkers associated with biological aging, assessed by quantitative polymerase chain reaction (qPCR), compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.

Trial sites (1)

FacilityCityRegionStatus
MusB Research LLC New Port Richey Florida Recruiting

Other trials for the same condition

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health Recruiting
Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage . Starting soon
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots Recruiting
A Novel Computer-Based Functional Skills Assessment and Training Program Active, not recruiting
Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07407894 on ClinicalTrials.gov ↗ ← All trials in the USA